Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
$10.30
$9.72
$18.20
$450MN/A2.07 million shs40,482 shs
IMV Inc. stock logo
IMV
IMV
$0.66
$0.48
$12.70
$9.63M0.95233,607 shs44,800 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.04
C$0.04
C$0.04
C$0.10
C$7.92M0.7160,559 shs9,157 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.05
+2.3%
$0.05
$0.04
$17.00
$236K1.75436,813 shs26,089 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00%0.00%0.00%0.00%0.00%
IMV Inc. stock logo
IMV
IMV
0.00%0.00%0.00%0.00%0.00%
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00%0.00%-20.00%-11.11%-20.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
+2.27%-18.18%-7.22%-92.86%-99.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
N/AN/AN/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
2.552 of 5 stars
3.53.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00
N/AN/AN/A
IMV Inc. stock logo
IMV
IMV
0.00
N/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
3.00
Buy$40.0088,788.89% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A$0.56 per shareN/A
IMV Inc. stock logo
IMV
IMV
$330K0.00N/AN/A($0.69) per share0.00
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.23) per shareN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
-$7.92MN/A0.00N/AN/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$2.81M-C$0.02N/AN/AN/A6.06%-34.90%N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%8/6/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A7.02%N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
0.37
0.37
IMV Inc. stock logo
IMV
IMV
N/A
2.93
2.93
Resverlogix Corp. stock logo
RVX
Resverlogix
-10.95
0.13
0.04
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
IMV Inc. stock logo
IMV
IMV
15.37%
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
IMV Inc. stock logo
IMV
IMV
0.33%
Resverlogix Corp. stock logo
RVX
Resverlogix
42.66%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A37.50 millionN/ANot Optionable
IMV Inc. stock logo
IMV
IMV
9711.71 million11.67 millionOptionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19197.94 millionN/ANot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Vincerx Pharma announces plan to delist from Nasdaq
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
Vincerx Pharma announces termination of reverse merger term sheet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Forest Road Acquisition stock logo

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

IMV stock logo

IMV NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Resverlogix stock logo

Resverlogix TSE:RVX

C$0.04 0.00 (0.00%)
As of 06/30/2025 03:45 PM Eastern

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.04 +0.00 (+2.27%)
As of 07/1/2025 03:12 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.